To examine antihypertensive effect and safety of administration of CS-3150 in combination with ARB or ACE inhibitor in hypertensive patients with moderate renal impairment.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
58
CS-3150 1.25 to 2.5, 5mg, orally
Unnamed facility
Nagano, Japan
Change from baseline in sitting systolic and diastolic blood pressure
Change from baseline in sitting systolic and diastolic blood pressure
Time frame: Baseline to end of Week 12
Time course of systolic and diastolic blood pressure
Time course of systolic and diastolic blood pressure
Time frame: Baseline to end of Week 12
Proportion of patients achieving blood pressure control
Proportion of patients achieving blood pressure control
Time frame: Baseline to end of Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.